• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Predicted cardiac and second cancer risks for patients undergoing VMAT for mediastinal Hodgkin lymphoma
CONCLUSION: For patients with mediastinal lymphoma excess mortality risks from CVD and second cancers remain clinically significant despite contemporary chemotherapy and photon-RT. Efforts to reduce the toxicity of combined modality treatment, for example, using DIBH, reduced margins and advanced RT, e.g. proton beam therapy, should be continued to further reduce potentially fatal treatment effects.PMID:36585562 | DOI:10.1007/s12094-022-03034-z
Source: Clinical Genitourinary Cancer - December 30, 2022 Category: Cancer & Oncology Authors: Orla A Houlihan Georgios Ntentas David J Cutter Patricia Daly Charles Gillham Orla McArdle Frances K Duane Source Type: research

Healthcare systems data in the context of clinical trials - A comparison of cardiovascular data from a clinical trial dataset with routinely collected data
CONCLUSION: Concordance between datasets was lower than anticipated and the HSD used could not straightforwardly replace current trial practices, nor directly identify protocol-defined CVS events. Further work is required to improve the quality of HSD and consider event definitions when designing clinical trials incorporating HSD.PMID:36933612 | DOI:10.1016/j.cct.2023.107162
Source: Clinical Lung Cancer - March 18, 2023 Category: Cancer & Oncology Authors: Archie Macnair Matthew Nankivell Macey L Murray Stuart D Rosen Sally Appleyard Matthew R Sydes Sylvia Forcat Andrew Welland Noel W Clarke Stephen Mangar Howard Kynaston Roger Kockelbergh Abdulla Al-Hasso John Deighan John Marshall Mahesh Parmar Ruth E Lan Source Type: research

Predicted cardiac and second cancer risks for patients undergoing VMAT for mediastinal Hodgkin lymphoma
ConclusionFor patients with mediastinal lymphoma excess mortality risks from CVD and second cancers remain clinically significant despite contemporary chemotherapy and photon-RT. Efforts to reduce the toxicity of combined modality treatment, for example, using DIBH, reduced margins and advanced RT, e.g. proton beam therapy, should be continued to further reduce potentially fatal treatment effects.
Source: Clinical and Translational Oncology - April 23, 2023 Category: Cancer & Oncology Source Type: research

Interpersonal Values of Patients Participating in Phase II –III Clinical Trials: Implications for Clinical Trial Representativeness
ConclusionsThis novel analysis of the interpersonal values of patients that participate in Phase II and III clinical trials revealed that the patients ’ interpersonal values largely differed from those of the Portuguese normative population. Better understanding the implications of these findings for clinical trial representativeness and outcomes is of crucial importance.
Source: Pharmaceutical Medicine - May 30, 2023 Category: Drugs & Pharmacology Source Type: research

Pages: 1  2  3